Item Brochure

ManualsBrandsRoche ManualsBlood Glucose TestsAccutrend® - Plus Meter Kit

COBAS, ACCUTREND and LIFE NEEDS ANSWERS

are trademarks of Roche.

Roche Diagnostics Ltd.

CH-6343 Rotkreuz

Switzerland

www.roche.com

Quick! Who needs to be screened

for cardiovascular disease?

Accutrend Plus: Spot on. On the spot.

05118441001

0000

References

1 Klingman, D., et al. (2005), Gauging the treatment gap in dyslipidemia: ﬁndings from the 1999–2000

National Health and Nutrition Examination Survey. Am Heart J 150: 595–601

2 WHO, MacKay, J. and Mensah, G.A. (2004), The Atlas of Heart Disease and Stroke

3 Cardium Study #4, Dyslipidemia Decision Resources, Inc. Waltham, MA (2007)

4 Yach, D., et al. (2004), The global burden of chronic diseases: overcoming impediments to prevention

and control. JAMA 291: 2616–2622

5 Clearﬁeld, M.B. (2003), Underidentiﬁcation and undertreatment of dyslipidemia.

J Am Osteopath Assoc 103: 5-8

6 Petersen, S., et al. (2005) European cardiovascular disease statistics. 2nd Edition.

European Heart Network and the British Heart Foundation

7 Taylor, J.R. and Lopez, A.M. (2004), Cholesterol: point-of-care testing. Ann Pharmacother 38: 1252–1257

8 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert

Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment

Panel III) (2001) JAMA 285: 2486–2497

9 ACE guidelines for Glycemic Control. Endocrine Pract. (2002) 8 (Suppl 1)

10 ADA guidelines Diabetes Care. (2006) 29 (Suppl 1): 4-42

11 Grundy, S.M., et al. (2005) Diagnosis and Management of the Metabolic Syndrome: An American

Heart Association/National Heart, Lung, and Blood Institute Scientiﬁc Statement: Executive Summary.

Circulation 112: 285–290

12 Tonkin, A. (2004) The metabolic syndrome – a growing problem. Eur. Heart J. 6 (Suppl A): A37-A42

13 Shaw, D.I., et al. (2005) Metabolic syndrome: what is it and what are the implications?

Proc Nutr Soc 64: 349-57

Summary of content (4 pages)

PAGE 1
References 1 Klingman, D., et al. (2005), Gauging the treatment gap in dyslipidemia: findings from the 1999–2000 National Health and Nutrition Examination Survey. Am Heart J 150: 595–601 2 WHO, MacKay, J. and Mensah, G.A. (2004), The Atlas of Heart Disease and Stroke 3 Cardium Study #4, Dyslipidemia Decision Resources, Inc. Waltham, MA (2007) 4 Yach, D., et al. (2004), The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 291: 2616–2622 5 Clearfield, M.B.
PAGE 2
It is a hard fact – 56.3% of people suffering from dyslipidemia have not been diagnosed.1 This is alarming considering that conventional risk factors account for around three quarters of all cardiovascular diseases (CVD).2 Characterised by abnormal levels of cholesterol and triglycerides (TGs), dyslipidemia currently affects more than 350 million people in the USA, Europe and Japan.3 But because it is a modifiable risk factor, this number could be improved given simple, reliable screening.
PAGE 3
Detecting the risk on the spot Three simple steps, accurate results The Accutrend® Plus system from Roche is a flexible, hand-held point of care device for the three key parameters – total cholesterol, triglycerides and glucose. A cost effective, all-in-one device that provides excellent assay performance when compared with standard laboratory tests.* You can also store up to 100 different measurements with date, time and high-low flags.
PAGE 4
Key values to detect and monitor CVD Accutrend Plus – Test Parameters Metabolic syndrome increases the risk of developing CVD¹¹ Metabolic syndrome increases the risk of CVD and type 2 diabetes. The worldwide prevalence is rising due to increasing obesity and sedentary life styles.11 Metabolic syndrome is estimated to be present in 24% of the US adult population12 and 15% for the same group in Europe.13 Patients with CVD typically have high total cholesterol in their blood.